BioPharm News

Sep 20, 2018
By BioPharm International Editors
The agreement now includes 15 European Union (EU) member states.
Sep 20, 2018
By BioPharm International Editors
The CHF 400-million (US$416-million) investment in Lonza's biopark in Visp, Switzerland, will expand Ibex Solutions with two new offerings, drug substance development and drug substance and drug product manufacturing.
Sep 19, 2018
By BioPharm International Editors
Colin Clarke, from the National Institute for Bioprocessing Research and Training, will lead a four-year European Industrial Doctoral Program for enhancing upstream biopharmaceutical manufacturing process development through single cell analysis.
Sep 19, 2018
By BioPharm International Editors
PCI Pharma Services and CSP Technologies will partner on protective packaging solutions for clinical trials and stability testing.
Sep 19, 2018
By BioPharm International Editors
The drug particle engineering and nanotechnology company offers a nanotechnology platform that can revive failed drugs in the pharma pipeline.
Sep 19, 2018
By BioPharm International Editors
The companies have partnered to launch Conjugated Polymer Nanoparticle (CPN) products for use in molecular imaging and R&D applications.
Sep 17, 2018
By BioPharm International Editors
The provider of plant-based ingredients will present recently launched multi-compendial materials for upstream and downstream biopharmaceutical applications.
Sep 17, 2018
By BioPharm International Editors
In the second half of CPhI’s annual report, experts review industry trends and warn that trade and patent changes could increase healthcare cost by $100 billion over the next five years.
Sep 17, 2018
By BioPharm International Editors
FDA sent a warning letter to Lernapharm (Loris) Inc. detailing the company’s lack of procedures to prevent microbiological contamination.
Sep 14, 2018
By BioPharm International Editors
The agency approved AstraZeneca’s Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia.
native1_300x100
lorem ipsum